Please assess the completion status of the following clinical trial:

Trial Title: A Phase 1/2 Study of HKI-272 (Neratinib) in Combination With Paclitaxel (Taxol) in Subjects With Solid Tumors and Breast Cancer

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~Inclusion criteria for both parts of clinical trial:~* Good performance status~* Normal ejection fraction~* Adequate cardiac, kidney, and liver function~* Adequate blood counts~* At least one measurable target lesion~* Negative pregnancy test for female subjects~Inclusion Criteria for Part 1 Only:~- Pathologically confirmed solid tumor not curable with available standard therapy~Inclusion Criteria for Part 2 Only:~* Pathologically confirmed breast cancer~* HER2 positive tumor~* Prior treatment with Herceptin~Exclusion Criteria:~Exclusion criteria for both parts of clinical trial:~* Major surgery, radiotherapy, chemotherapy or investigational agents within two weeks of treatment day 1~* Subjects with bone or skin as the only site of disease~* Active central nervous system metastases~* Significant cardiac disease or dysfunction~* Significant gastrointestinal disorder~* Inability or unwillingness to swallow HKI-272 capsules~* Prior exposure to HKI-272 or other HER2 targeted agents, except trastuzumab (Part 2 only). Prior lapatinib is permitted in arm B of part 2.~* Treatment with a taxane within 3 months of treatment day 1~* Grade 2 or greater motor or sensory neuropathy~* Pregnant or breast feeding women~* Known hypersensitivity to paclitaxel or Cremophor EL~* Prior treatment with anthracyclines with cumulative dose of \>400 mg/m\^2~* Any other cancer within 5 years with the exception of contralateral breast cancer, adequately treated cervical carcinoma in situ, or adequately treated basal or squamous cell carcinoma of the skin~Exclusion Criteria for Part 2 Only:~- More than 1 (arm A) or 3 (arm B) prior cytotoxic chemotherapy regimen for metastatic disease

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- HKI-272 dose level 1 (Type: EXPERIMENTAL): Part 1: Subjects with solid tumors receiving HKI-272 (neratinib) 160 mg daily by mouth in combination with paclitaxel 80 mg/m\^2 weekly IV.
- HKI-272 dose level 2 (Type: EXPERIMENTAL): Part 1: Subjects with solid tumors receiving HKI-272 (neratinib) 240 mg daily by mouth in combination with paclitaxel 80 mg/m\^2 weekly IV.
- HKI-272 expanded MTD cohort, arm A (Type: EXPERIMENTAL): Part 2: Subjects with metastatic breast cancer who have not received more than 1 prior cytotoxic chemotherapy treatment regimen for metastatic disease receiving HKI-272 (neratinib) 240 mg daily by mouth in combination with paclitaxel 80 mg/m\^2 weekly IV.
- HKI-272 expanded MTD cohort, arm B (Type: EXPERIMENTAL): Part 2: Subjects with metastatic breast cancer who have not received more than 3 prior cytotoxic chemotherapy treatment regimen for metastatic disease receiving HKI-272 (neratinib) 240 mg daily by mouth in combination with paclitaxel 80 mg/m\^2 weekly IV.

Based on this trial design, predict the completion outcome and termination type (if applicable).